Pfizer CEO Albert Bourla has detailed the pharmaceutical company's strategic pivot following the COVID-19 pandemic, emphasizing a renewed focus on cancer treatments and the development of new obesity medications. Bourla acknowledged the significant psychological impact of the company's performance shift from peak pandemic success to a post-COVID slump, stating, "To go from the top performer to the bottom performer—although not in everything, but in stock price, for example—was something that I didn’t take lightly." He rallied his organization by highlighting past achievements and setting new ambitious goals, particularly in oncology. "You were the guys that saved the world when nobody thought that it could be saved. And you did it in ways that nobody thought it was possible. Guess what? We are going to do it again, with cancer this time,” Bourla said.
In the competitive landscape of obesity treatments, Pfizer aims to differentiate its offerings by developing drugs that require monthly injections, a less frequent regimen than some competitors currently provide. This move signals a strategic effort to regain market prominence in a rapidly growing therapeutic area.
Bourla also addressed his relationship with Health Secretary Robert F. Kennedy Jr., noting areas of disagreement, particularly concerning vaccines. However, he expressed a willingness to collaborate on issues where their views align to build trust and address other health challenges. "I told him that there are things that we have very different views [on]—vaccines, for example. If we select the areas that don’t have that big of a difference and try to work together to produce something good ... that will create a bonding and will take away the trust issues, and then we can tackle the vaccines,” Bourla stated.
Responding to concerns about the pharmaceutical industry's "revolving door" between government and industry, a practice criticized by Kennedy Jr., Bourla defended the hiring of a former top FDA official as Pfizer's chief medical officer. The official had previously worked at Pfizer before joining the FDA. Bourla also weighed in on the possibility of building a medical supply chain independent of China. He expressed that a reliance on China for medicine supply chains is not ideal, but acknowledged that establishing domestic manufacturing requires significant market incentives. "I don’t think it’s a good thing to have a reliance on the supply chain of China when it comes to medicines," he said, adding, "I think we can, but we need to provide market incentives. There was a reason why medicines that used to be manufactured in the U.S. moved out."
Bourla reiterated Pfizer's commitment to speed in drug development, framing it as a critical factor in saving lives. "Time is life," he asserted. "Bringing medicine for a cancer patient earlier makes all the difference in the world. If that medicine will allow someone to see the wedding of the son or the graduation of the daughter, there is nothing more important in their life, and speed is what will allow them to do it." This philosophy underscores Pfizer's approach to innovation and its dedication to accelerating the delivery of life-saving therapies.